FIELD: chemistry.
SUBSTANCE: invention relates to field of biotechnology, namely to obtaining modified glucagon peptides, and can be used in medicine. Obtained is glucagon peptide with glucagon agonist activity, characterised by amino acid sequence SEQ ID NO: 1, containing up to 7 amino acid substitutions with respect to SEQ ID NO: 1, where one of amino acid substitutions represents substitution of glutamine in position 3 of sequence. SEQ ID NO: 1 for amino acid, containing side chain of structure I, and where amino acid in position 16 of glucagon peptide represents aminoisobutyric acid (AIB).
EFFECT: invention makes it possible to obtain glucagon agonists, possessing higher solubility and stability.
12 cl, 17 dwg, 12 tbl, 28 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INSULIN-INCRETIN CONJUGATES | 2014 |
|
RU2678134C2 |
| AMIDE-BASED PRODRUGS OF GLUCAGON SUPERFAMILY PEPTIDES | 2009 |
|
RU2550696C2 |
| GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE RECEPTOR ACTIVITY | 2011 |
|
RU2604067C2 |
| GLUCAGON ANALOGUES, HAVING HIGH SOLUBILITY IN PHYSIOLOGICAL pH BUFFERS | 2008 |
|
RU2477286C2 |
| PEPTIDE DRUGS WITH HIGH EFFECTIVENESS AGAINST INSULIN RESISTANCE | 2012 |
|
RU2602801C2 |
| PEPTIDE PRO-DRUGS OF AMIDE GLUCAGON SUPERFAMILY | 2011 |
|
RU2580317C2 |
| OXYINTOMODULINE | 2009 |
|
RU2542362C2 |
| MODIFIED ANALOGUES OF GIP PEPTIDE | 2019 |
|
RU2817673C2 |
| DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | 2013 |
|
RU2652783C2 |
| TREATMENT OF NEUROLOGICAL DISEASES | 2017 |
|
RU2755997C2 |
